PubRank

C Romei

Author PubWeight™ 23.28‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996 3.27
2 Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. J Clin Endocrinol Metab 2015 2.41
3 Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994 2.05
4 Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006 1.33
5 RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab 2001 1.31
6 Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab 1997 1.25
7 Simian virus 40-like DNA sequences in human papillary thyroid carcinomas. Oncogene 1998 0.90
8 Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype. J Clin Endocrinol Metab 1994 0.86
9 Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer. Eur J Cancer 1994 0.86
10 RET proto-oncogene mutations in thyroid carcinomas: clinical relevance. J Endocrinol Invest 2000 0.85
11 Identification of the Cys634-->Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis. J Endocrinol Invest 1994 0.84
12 Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers 1994 0.82
13 Neuropeptide S selectively inhibits the release of 5-HT and noradrenaline from mouse frontal cortex nerve endings. Br J Pharmacol 2009 0.82
14 Polyclonal origin of medullary carcinoma of the thyroid in multiple endocrine neoplasia type 2. Hum Genet 1997 0.82
15 In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. Endocr Relat Cancer 2011 0.81
16 Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Surgery 1995 0.80
17 Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene. Oncogene 1997 0.78
18 A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure. J Clin Endocrinol Metab 2004 0.78
19 Transfection with the cDNA of the human thyrotropin receptor of a poorly differentiated rat thyroid cell line (FRT). J Endocrinol Invest 1996 0.76
20 Determinants of the prognosis of idiopathic pulmonary fibrosis. Eur Rev Med Pharmacol Sci 2014 0.76
21 New breakpoints in both the H4 and RET genes create a variant of PTC-1 in a post-Chernobyl papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2000 0.75
22 Post-surgical follow-up of differentiated thyroid cancer. J Endocrinol Invest 1995 0.75
23 Development of anthropomorphic hand phantoms for personal dosimetry in 90Y-Zevalin preparation and patient delivering. Radiat Prot Dosimetry 2013 0.75
24 Treatment of preclinical medullary thyroid carcinoma in MEN 2A gene carrier. Lancet 1994 0.75